Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $2

Benzinga · 2d ago
Piper Sandler analyst Allison Bratzel maintains Akebia Therapeutics (NASDAQ:AKBA) with a Overweight and lowers the price target from $4 to $2.